Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05904886 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
A Phase 3 study of Hepatocellular Carcinoma, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 687
- Enrollment target
- 20
- Study locations
NCT05904886 is a Phase 3 study of Hepatocellular Carcinoma that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 687 participants, above the 253-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (172% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT05904886, a Phase 3 study of Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 687 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic HCC. Per amendment version 5, following a memo issued by the Sponsor, participants receiving treatment in the atezolizumab plus bevacizumab plus tiragolumab arm are recommended to discontinue tiragolumab treatment unless the investigator decides the benefit outweighs the risk. Participants receiving treatment in atezolizumab plus bevacizumab plus placebo arm must discontinue placebo treatment. Participants may continue receiving active treatment(s) per protocol until loss of clinical benefit or unacceptable toxicity, whichever occurs first.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- OTHER Placebo
- DRUG Tiragolumab
Study Locations (20)
California
- UCSF Fresno at Community Cancer Institute - Clovis
- City of Hope Cancer Center - Duarte
- University of California San Diego Moores Cancer Center - La Jolla
- University of Southern California - Los Angeles
- Stanford Cancer Center - Palo Alto
- Va Palo Alto Health Care System - Palo Alto
- UCLA Cancer Center - Santa Monica
Florida
- Florida Cancer Specialists - Fort Myers (Broadway) - Fort Myers
- Miami VA Healthcare System - Miami
- Florida Cancer Specialist, North Region - St. Petersburg
Michigan
- Henry Ford Health System - Detroit
- Cancer & Hematology Centers of Western Michigan - Grand Rapids
Arkansas
- Genesis Cancer Center - Hot Springs
Connecticut
- Hartford Healthcare Cancer Institute at Hartford Hospital - Hartford
District of Columbia
- MedStar Washington Hosp Center - Washington D.C.
Illinois
- University of Illinois - Chicago
Kentucky
- Norton Cancer Institute - Audubon - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 687 participants |
| Start Date | 2023-09-14 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05904886
The ClinicalTrials.gov registry entry for NCT05904886 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 687 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 253-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (172% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.
NCT05904886 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT05904886 about?
NCT05904886 is a clinical study titled "A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)". The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic HCC. Per amendment version ...
What is the current status of trial NCT05904886?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 687 participants. The study started on 2023-09-14. Estimated completion is 2026-09-01.
What conditions does trial NCT05904886 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT05904886?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Placebo (OTHER), Tiragolumab (DRUG).
Who is sponsoring clinical trial NCT05904886?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05904886 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
RECRUITING · Phase 3
-
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RECRUITING · Phase 3
-
Evaluating Novel Therapies in ctDNA Positive GI Cancers
RECRUITING · Phase 3
-
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
ACTIVE NOT RECRUITING · Phase 3
-
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.